HEPATITIS C CLINICAL TRIAL-CLINICAL CENTERS

该项目旨在开发实用、安全和有效的手段， 预防慢性肝病患者的肝脏疾病进展 丙型肝炎病毒（HCV）感染。 约800名患者， 慢性丙型肝炎患者对α治疗无效 干扰素（含或不含利巴韦林）和严重纤维化患者 将参加一项关于 持续的长期抗病毒治疗（长达四年）。的 本试验的目的是评估是否连续治疗， 长期抗病毒治疗可以减缓肝病的进展， 预防肝硬化或预防肝硬化恶化，失代偿， 肝细胞癌（HCC）的发展和肝脏死亡 疾病 试验还将评估肝炎的自然史 C和预测疾病进展或与疾病进展相关的因素。 的 主要重点将是评估是否抗病毒治疗，尽管没有 导致HCV的根除，可以抑制肝细胞损伤， 坏死和纤维化。 慢性丙型肝炎患者 以前用α干扰素治疗， 病毒学和生化应答者将有资格进入试验。

This project is aimed at developing practical, safe and effective means of preventing the progression of liver disease in patients with chronic hepatitis C virus (HCV) infection. Approximately 800 patients with chronic hepatitis C who have failed to respond to therapy with alpha interferon (with or without ribavirin) and who have significant fibrosis on liver biopsy will be enrolled in a study of the efficacy and safety of a continuous long-term antiviral therapy (for as long as four years). The objective of the Trial is to evaluate whether continuous therapy with long-term antiviral therapy can slow the progression of liver disease, preventing cirrhosis or preventing worsening of cirrhosis, decompensation, development of hepatocellular carcinoma (HCC) and death from liver disease. The Trial will also evaluate the natural history of hepatitis C and the factors that predict or correlate with disease progression. The major focus will be to evaluate whether antiviral therapy, despite not leading to eradication of HCV, can suppress hepatocellular injury, necrosis and fibrosis. Patients with chronic hepatitis C who have previously been treated with alpha interferon without a sustained virological and biochemical response will be eligible to enter the Trial.